Clinical Trial

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life and functioning of people who are affected. This study is seeking participants who: * Are 18 to 70 years old * Have had moderate-to-severe asthma for at least 12 months that is not well controlled * Have been taking their regular maintenance treatment(s) for asthma over the last 12 months All participants will receive PF-07275315 or a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. PF-07275315 or placebo will be given as multiple shots in the clinic over the course of 12 weeks. We will compare the experiences of people receiving PF-07275315 to those of the people who do not. This will help us determine if PF-07275315 is safe and effective. Participants will be involved in this study for about 7.5 months. During this time, they will have 9 visits at the study clinic.
Protocol Amendment History 1 change
notable Trial sites expanded: 125 -> 132 locations 2026-05-05
Trial Details
NCT Number NCT06977581
Lead Sponsor Pfizer
Conditions Asthma
Enrollment 252 participants
Start Date 2025-05-20
Primary Completion 2027-03-08 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-04